Literature DB >> 18983337

Insulin resistance and endothelin: another pathway for renal injury in patients with the cardiometabolic syndrome?

Pantelis A Sarafidis1, Anastasios N Lasaridis.   

Abstract

Recent population studies suggest that insulin resistance and hyperinsulinemia, as well as the presence of the cardiometabolic syndrome, are associated with increased risk of chronic kidney disease. A considerable number of background studies support this association, proposing several mechanisms through which insulin resistance and hyperinsulinemia can harm the normal kidney. Current knowledge suggests that activation of the endothelin system can be an important factor contributing to the development of renal injury. Moreover, data from in vitro and in vivo studies have clearly shown that hyperinsulinemia stimulates the production and action of endothelin-1, an effect that is sustained in insulin-resistant states. Thus, insulin-mediated activation of the endothelin system can be another important pathway linking insulin resistance with kidney injury. This article discusses the existing data on the interactions between insulin resistance, hyperinsulinemia, and endothelin and how these can lead to renal damage in patients with the cardiometabolic syndrome.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18983337     DOI: 10.1111/j.1559-4572.2008.00009.x

Source DB:  PubMed          Journal:  J Cardiometab Syndr        ISSN: 1559-4564


  9 in total

Review 1.  Epidemiology of obesity, the metabolic syndrome, and chronic kidney disease.

Authors:  Rikki M Tanner; Todd M Brown; Paul Muntner
Journal:  Curr Hypertens Rep       Date:  2012-04       Impact factor: 5.369

2.  Longitudinal relationships of metabolic syndrome and obesity with kidney function: Healthy Twin Study.

Authors:  Yun-Mi Song; Joohon Sung; Kayoung Lee
Journal:  Clin Exp Nephrol       Date:  2015-01-30       Impact factor: 2.801

3.  Diabetic nephropathy: Endothelin antagonism for diabetic nephropathy.

Authors:  Pantelis A Sarafidis; Anastasios N Lasaridis
Journal:  Nat Rev Nephrol       Date:  2010-08       Impact factor: 28.314

Review 4.  Endothelin, hypertension and chronic kidney disease: new insights.

Authors:  Donald E Kohan
Journal:  Curr Opin Nephrol Hypertens       Date:  2010-03       Impact factor: 2.894

5.  Chronic kidney disease among overweight and obesity with and without metabolic syndrome in an urban Chinese cohort.

Authors:  Xia Cao; Jiansong Zhou; Hong Yuan; Liuxin Wu; Zhiheng Chen
Journal:  BMC Nephrol       Date:  2015-06-18       Impact factor: 2.388

6.  Association of cardiac NT pro-β-type natriuretic peptide with metabolic and endothelial risk factors in young obese hypertensive patients: a perspective on the hypothalamic pituitary adrenal axis activation.

Authors:  Mona Schaalan; Waleed Mohamed; Rania Rahmo
Journal:  Diabetol Metab Syndr       Date:  2016-07-29       Impact factor: 3.320

7.  Metabolic Syndrome and Obesity-Related Indices Are Associated with Rapid Renal Function Decline in a Large Taiwanese Population Follow-Up Study.

Authors:  Wei-Yu Su; I-Hua Chen; Yuh-Ching Gau; Pei-Yu Wu; Jiun-Chi Huang; Yi-Chun Tsai; Szu-Chia Chen; Jer-Ming Chang; Shang-Jyh Hwang; Hung-Chun Chen
Journal:  Biomedicines       Date:  2022-07-19

8.  Proposal for standardizing normal insulin ranges in Brazilian patients and a new classification of metabolic syndrome.

Authors:  Pedro Renato Chocair; Precil Diego Miranda de Menezes Neves; Victor Augusto Hamamoto Sato; Sara Mohrbacher; Érico Souza Oliveira; Leonardo Victor Barbosa Pereira; Alessandra Martins Bales; Fagner Pereira da Silva; John A Duley; Américo Lourenço Cuvello-Neto
Journal:  Front Med (Lausanne)       Date:  2022-09-09

9.  Long-term Body Weight Gain After Maturity is Associated With the Incidence of Chronic Kidney Disease (CKD), Independent of Current Body Weight, in Middle-aged and Older Men.

Authors:  Ryoma Michishita; Takuro Matsuda; Shotaro Kawakami; Satoshi Tanaka; Akira Kiyonaga; Hiroaki Tanaka; Natsumi Morito; Yasuki Higaki
Journal:  J Epidemiol       Date:  2018-10-20       Impact factor: 3.211

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.